Search This Blog

Friday, September 25, 2026

Novo Nordisk wins Singapore approval of injectable Wegovy for noncirrhotic MASH

 

Novo Nordisk wins Singapore approval of injectable Wegovy for noncirrhotic MASH with moderate-to-advanced fibrosis

  • Approval expands Wegovy’s indications in Singapore beyond weight management to include treatment of noncirrhotic MASH with moderate-to-advanced fibrosis.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)